Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 697-urethral-stricture
    Ask Trek AI about this page

    Urethral Stricture: Inpatient Reimbursement Overview

    DRG 697 encompasses inpatient encounters for treatment of urethral stricture, including dilation, urethrotomy, and reconstructive approaches; it defines the clinical scope for grouping services related to relief of urethral obstruction. This grouping matters for inpatient reimbursement because it determines the bundled payment hospitals receive from the Centers for Medicare & Medicaid Services under the Medicare Severity Diagnosis-Related Group system.

    Customize your policy alerts

    Sign up for drg 697 policy alerts

    Get alerted when payer policies referencing 697 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 697 Overview

    DRG 697 covers inpatient admissions for urethral stricture procedures and related management, typically involving urethral dilation, urethrotomy, reconstruction, or catheter-related interventions. This Diagnosis-Related Group captures cases where the primary focus is correction or palliation of urethral narrowing that impairs urinary flow. For Medicare payment, DRG 697 groups clinically similar hospital stays to determine bundled reimbursement for facility services during the inpatient encounter. Accurate coding and documentation of procedures and any Complication or Comorbidity or Major Complication or Comorbidity affect payment assignment within the Medicare Severity Diagnosis-Related Group structure.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Studies evaluating novel minimally invasive urethral dilation and internal urethrotomy techniques: These trials compare short-term and long-term patency outcomes, complication rates, and time to re-intervention for different minimally invasive procedures in adult men with bulbar or penile urethral strictures. The patient population typically includes those with single short strictures or recurrent disease managed without open reconstruction, and results inform inpatient procedure selection, length of stay, and expected resource use relevant to hospital billing and payer authorization.
    • Comparative effectiveness research on urethroplasty approaches and timing: Randomized or observational cohort studies contrast excisional primary anastomosis, graft (buccal mucosa) substitution urethroplasty, and staged repairs across patients with varying stricture length, location, and etiology (traumatic, iatrogenic, or inflammatory). These studies address recurrence rates, functional outcomes (voiding and sexual function), perioperative morbidity, and readmission rates, providing evidence that influences DRG-level cost profiles, decisions about inpatient versus outpatient pathways, and long-term reimbursement considerations.
    • Post-discharge outcomes and health services research focusing on recurrence, re-intervention, and quality of life: Longitudinal registry-based or prospective cohort studies follow patients after index admission for strictures to measure rates of repeat procedures, urinary tract infections, catheter dependence, patient-reported urinary function, and healthcare utilization over months to years. This research is relevant to payers and providers by quantifying downstream costs, identifying predictors of high resource use, and informing care coordination, follow-up protocols, and value-based payment models for patients assigned to this DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.